{
  "first_published_at": "2010-05-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON085170", 
  "title": "Panitumumab (Vectibix): serious hypersensitivity reactions", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 203, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Panitumumab (Vectibix): serious hypersensitivity reactions</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: May 2010</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--There have been new reports of serious hypersensitivity reactions (including anaphylaxis) in patients receiving panitumumab, some of which were fatal.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Panitumumab (Vectibix) is indicated as monotherapy for the treatment of patients with EGFR (epidermal growth factor receptor)-expressing metastatic colorectal carcinoma with non-mutated (wild type) <em>KRAS</em> after failure of chemotherapy regimens.</p><p>There have been new reports of serious hypersensitivity reactions (including anaphylaxis) in patients receiving panitumumab, some of which were fatal.</p><p>A clinical trial report has been received of a fatal case of angioedema occurring 2 days after exposure following a prior episode of angioedema which occurred 6 days after exposure. Recently, two case reports of fatal hypersensitivity reactions during and immediately following panitumumab infusion have been received; these patients had previously experienced hypersensitivity reactions to cetuximab and oxaliplatin, respectively.</p><p>Product information has been updated to highlight the following:</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Panitumumab is contraindicated in patients with a history of severe or life-threatening hypersensitivity reactions to this medicine</li>\r\n\t\t\t\t<li>Serious infusion-related reactions are unpredictable and can occur suddenly. Panitumumab should be permanently discontinued if a severe or life-threatening reaction occurs</li>\r\n\t\t\t\t<li>In patients with a mild or moderate infusion-related reaction, the infusion rate should be reduced for the duration of the infusion; it is recommended to maintain this lower infusion rate in all subsequent infusions</li>\r\n\t\t\t\t<li>Hypersensitivity reactions occurring more than 24 hours after infusion have also been reported. Patients should be warned of a possible late-onset reaction and instructed to contact their physician if symptoms of<br>    hypersensitivity occur</li>\r\n\t\t\t</ul></div><p><a href=\"ssLINK/CON081746\">A letter has been sent to relevant healthcare professionals to inform of these risks</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update May 2010, vol 3 issue 10: 8.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Panitumumab (Vectibix) is indicated as monotherapy for the treatment of patients with EGFR (epidermal growth factor receptor)-expressing metastatic colorectal carcinoma with non-mutated (wild type) <em>KRAS</em> after failure of chemotherapy regimens.</p><p>There have been new reports of serious hypersensitivity reactions (including anaphylaxis) in patients receiving panitumumab, some of which were fatal.</p><p>A clinical trial report has been received of a fatal case of angioedema occurring 2 days after exposure following a prior episode of angioedema which occurred 6 days after exposure. Recently, two case reports of fatal hypersensitivity reactions during and immediately following panitumumab infusion have been received; these patients had previously experienced hypersensitivity reactions to cetuximab and oxaliplatin, respectively.</p><p>Product information has been updated to highlight the following:</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Panitumumab is contraindicated in patients with a history of severe or life-threatening hypersensitivity reactions to this medicine</li>\r\n\t\t\t\t<li>Serious infusion-related reactions are unpredictable and can occur suddenly. Panitumumab should be permanently discontinued if a severe or life-threatening reaction occurs</li>\r\n\t\t\t\t<li>In patients with a mild or moderate infusion-related reaction, the infusion rate should be reduced for the duration of the infusion; it is recommended to maintain this lower infusion rate in all subsequent infusions</li>\r\n\t\t\t\t<li>Hypersensitivity reactions occurring more than 24 hours after infusion have also been reported. Patients should be warned of a possible late-onset reaction and instructed to contact their physician if symptoms of<br>    hypersensitivity occur</li>\r\n\t\t\t</ul></div><p><a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON081746\">A letter has been sent to relevant healthcare professionals to inform of these risks</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update May 2010, vol 3 issue 10: 8.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2010-05-01", 
  "date_last_modified": "2010-09-13", 
  "_assets": [], 
  "_item_id": 203, 
  "summary": "", 
  "body": "Article date: May 2010\n\nPanitumumab (Vectibix) is indicated as monotherapy for the treatment of patients with EGFR (epidermal growth factor receptor)-expressing metastatic colorectal carcinoma with non-mutated (wild type) KRAS after failure of chemotherapy regimens.\n\nThere have been new reports of serious hypersensitivity reactions (including anaphylaxis) in patients receiving panitumumab, some of which were fatal.\n\nA clinical trial report has been received of a fatal case of angioedema occurring 2 days after exposure following a prior episode of angioedema which occurred 6 days after exposure. Recently, two case reports of fatal hypersensitivity reactions during and immediately following panitumumab infusion have been received; these patients had previously experienced hypersensitivity reactions to cetuximab and oxaliplatin, respectively.\n\nProduct information has been updated to highlight the following:\n\nAdvice for healthcare professionals:  \n  \n  * Panitumumab is contraindicated in patients with a history of severe or life-threatening hypersensitivity reactions to this medicine  \n  * Serious infusion-related reactions are unpredictable and can occur suddenly. Panitumumab should be permanently discontinued if a severe or life-threatening reaction occurs  \n  * In patients with a mild or moderate infusion-related reaction, the infusion rate should be reduced for the duration of the infusion; it is recommended to maintain this lower infusion rate in all subsequent infusions  \n  * Hypersensitivity reactions occurring more than 24 hours after infusion have also been reported. Patients should be warned of a possible late-onset reaction and instructed to contact their physician if symptoms of  \nhypersensitivity occur  \n  \n[A letter has been sent to relevant healthcare professionals to inform of these risks](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON081746)\n\nÂ \n\nArticle citation: Drug Safety Update May 2010, vol 3 issue 10: 8.\n"
}